The Medication-use Evaluation
(MUE) Unit monitors drug utilisation and patient outcomes following treatment. This
process is conducted on medications on the Government Formulary List (GFL),
newly introduced drugs and non-formulary drugs currently being approved through
the Exceptional Medicinal Treatment Policy.
Medication-use Evaluation is a performance
improvement method focused on evaluating and improving medication-use processes
with the goal of achieving optimal patient outcomes. The process consists of a formal evidence-based analysis aimed to
assist stakeholders in determining what is working well and identify
opportunities for change.
Screening mechanisms are developed by DPA for the comprehensive
surveillance of medication use processes, setting up priorities as per
requirements on the NHS.
The roles of the individual health care professionals,
entities and stakeholders in MUE may vary according to practice setting,
organizational goals and available resources. Collaboration from other healthcare
professionals is vital as they contribute their unique perspectives when the
evaluation and improvement processes address their area of expertise and
responsibility.
MUE outcomes are compared to the pre-determined criteria.
Results of the evaluation are then discussed in further detail with stakeholders. Results
and recommendations of the MUE are submitted to health authorities and
stakeholders as required.